Paper Details

  1. Home
  2. Paper Details

[Effectiveness of the tenoxicam in patients with ankylosing spondylitis].

Author: AparkinaA V, GaydukovaI Z, KhondkaryanE V, RebrovA P

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigated the effect of tenoxicam on pain syndrome in patients with ankylosing spondylitis (AS) who had not responded to NSAIDs on the 'on-demand' basis. 40 patients were included. BASDAI and ASDAS indices decreased in patients treated with tenoxicam.
Paper Details　
Original Abstract of the Article :
AIM: To study the changes in pain syndrome and its characteristic in patients with ankylosing spondylitis (AS) who received tenoxicam after non-effective treatment with NSAIDs on the 'on-demand' basis. MATERIAL AND METHODS: Forty patients with AS, who had BASDAI ≥4.0 at baseline and after 52 weeks ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.17116/jnevro20181182135-39

データ提供：米国国立医学図書館（NLM）

Tenoxicam: A Potential Solution for Ankylosing Spondylitis

Ankylosing spondylitis (AS), a chronic inflammatory disease primarily affecting the spine, can cause significant pain and disability. This study evaluates the effectiveness of tenoxicam, a nonsteroidal anti-inflammatory drug (NSAID), in managing AS symptoms, specifically in patients who did not respond to other NSAIDs. The authors compared the outcomes of patients receiving tenoxicam to those who continued their previous therapy, providing insights into the efficacy and potential benefits of this drug in AS treatment.

A New Avenue for AS Management

The study's findings suggest that tenoxicam may offer a valuable therapeutic option for AS patients who have not responded to other NSAIDs. This study provides hope for individuals seeking effective symptom management and improved quality of life. The findings encourage further research to explore the long-term effects of tenoxicam and optimize its use in AS treatment.

Navigating the Path to Relief

This study, like a compass guiding us through the complexities of AS, explores the potential of tenoxicam as a treatment option. The findings emphasize the need for individualized approaches to AS management, considering the unique needs and responses of each patient. The study encourages us to continue searching for effective therapies that provide relief and improve the lives of individuals living with AS.

Dr.Camel's Conclusion

This study, like a desert traveler seeking a respite from the heat, explores the potential of tenoxicam to alleviate the pain and discomfort of ankylosing spondylitis. The findings suggest a promising new avenue for managing AS, offering hope for improved outcomes and enhanced quality of life for patients.

Date :
  1. Date Completed 2019-05-14
  2. Date Revised 2019-05-14
Further Info :

Pubmed ID

29560939

DOI: Digital Object Identifier

10.17116/jnevro20181182135-39

SNS
PICO Info
in preparation
Languages

Russian

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.